The FDA granted DBV Technologies, a clinical-stage specialty biopharmaceutical company based in Bagneux, France Breakthrough Designation (BTD) to its Viaskin Peanut for children. This BTD followed the positive results from the Phase IIb trial that demonstrated significant improvement among children with peanut allergy disease treated with Viaskin Peanut. Peanut allergy is a major type of food allergies affecting both children and adults that can result in anaphylaxis death. Viaskin is an electrostatic patch that administers an allergen directly onto the superficial layers of the skin to active the immune system without allowing passage of the antigen into the bloodstream. DBV is currently preparing the launch of its Phase III trial of this skin patch in children suffering from peanut allergy.